Pomegra
Scan.com's $220M Series C and debt package funds a push to become the largest diagnostic imaging network in the US, backed by Noteus Partners and Aviva.
- $90M equity led by Noteus Partners, plus $130M in debt from VerisFi Capital and Atempo Growth, closed August 31, 2026.
- Scan.com surpassed a $165M annualized revenue run rate after doubling revenue in the past twelve months.
- Total capital raised reaches approximately $277M; valuation undisclosed.
Lead
Scan.com, the UK-founded diagnostic imaging platform, closed $220 million in combined financing on August 31, 2026 - the largest capital raise in the company's history. The round includes a $90 million Series C equity tranche led by Paris-based Noteus Partners and a $130 million debt facility provided by VerisFi Capital and Atempo Growth. Nearly all of the capital is directed toward the United States, where the company is attempting to consolidate a fragmented $100 billion-plus imaging market under a single technology layer.
What Did Scan.com Raise and Who Backed It?
The $90 million equity portion attracted a range of institutional names alongside Noteus Partners: Aviva, Concord Health Partners, YZR Capital, and Oxford Capital all participated. The debt facility - larger than the equity tranche - signals that lenders are comfortable with the company's revenue trajectory. Valuation was not disclosed.
The structure carries a built-in tension. Funding a growth push with more debt than equity limits dilution for existing shareholders, but it also means the company carries fixed repayment obligations against future US revenue - a region where the network is still being assembled. That trade-off looks manageable at current growth rates, and considerably less comfortable if US expansion lags the timeline.
How Does Scan.com's Platform Work?
Scan.com operates as an intermediary layer between referring clinicians and imaging centers. Its API connects directly into electronic medical records, so doctors can order and schedule scans without leaving their existing systems. An agentic AI engine matches each referral against live availability, price, and radiology subspecialty across the network, then handles scheduling, prior-authorization paperwork, and results routing automatically. Human care guides stay with the patient throughout. Results typically return within 48 hours.
The platform has served more than 900,000 patients across the UK and the US. The US now accounts for most of the company's revenue and workforce, a shift that reflects both the scale of the American market and where the company has focused commercial effort since its earlier UK build-out.
Why Is the US the Target?
The US medical imaging market exceeds $100 billion annually and remains fragmented across independent imaging centers, hospital outpatient departments, and teleradiology groups - most operating without shared infrastructure. Long wait times, opaque pricing, and manual prior-authorization workflows create friction at nearly every step.
Scan.com's thesis is that an API-first network layer can extract enough efficiency from the scheduling and administrative workflow to justify national scale. The company doubled revenue over the past twelve months to hit a $165 million annualized run rate. That trajectory matters because it sets the floor for the US growth the debt facility is effectively underwriting.
The capital is also earmarked for M&A of regional scheduling networks, a faster path to density than organic expansion alone.
What Comes Next for Scan.com?
The company has held preliminary discussions with officials at the London Stock Exchange, raising the prospect of a public offering once revenue justifies the exercise. At a $165 million run rate and growing, the threshold is closer than it was at the last funding round - but IPO preparation routinely extends well past initial conversations, and no timeline has been announced.
The presence of Aviva in the equity tranche is a signal worth reading carefully. The insurer is more naturally at home in public markets than in early-stage venture, and its participation alongside growth equity investors suggests the cap table is already positioning for a liquidity event.
Outlook
Scan.com enters a competitive US healthtech environment with a well-defined product: infrastructure software and network access for diagnostic imaging. The $220 million raise buys the runway to find out whether a UK-founded network can reach the provider density in major US metros needed to shift clinician behavior at scale. The agentic AI layer is the differentiated bet - if it genuinely removes prior-authorization friction at the point of referral, health systems have clear incentive to connect. Whether the debt-heavy capital structure leaves enough headroom if US expansion takes longer than modeled is the question the next twelve months will answer.
